Semaglutide Drug Interactions: Complete Safety Guide 2026

Summary: Semaglutide slows gastric emptying, which shifts the absorption of orally administered drugs and amplifies hypoglycemia risk when stacked on insulin or sulfonylureas; almost every important interaction traces back to one of those two mechanisms.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short version: semaglutide has very few classical metabolic drug interactions. It is not a CYP450 inducer or inhibitor, it does not bind plasma proteins in a meaningful way, and it is cleared by proteolysis rather than the liver or kidney. The interactions that matter all come from one place: semaglutide slows gastric emptying. That single pharmacokinetic effect changes how every orally administered drug reaches your bloodstream, and it stacks dangerously with any medication that already lowers blood glucose.

Below is the full interaction map, mechanism by mechanism, with the specific drugs the FDA Ozempic, Wegovy, and Rybelsus labels actually call out.

The one mechanism behind almost every interaction

Semaglutide is a GLP-1 receptor agonist. It works partly by suppressing appetite in the brain and partly by delaying how fast the stomach empties food and pills into the small intestine. That delayed gastric emptying is the main pharmacokinetic interaction pathway. The Ozempic label states directly: "Semaglutide causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications" ^[1].

Two things follow from that. First, drugs absorbed in the upper small intestine reach peak blood levels later and sometimes lower. Second, drugs with a narrow therapeutic window (warfarin, levothyroxine, antiepileptics, lithium) need closer monitoring when you start, escalate, or stop semaglutide. The effect is largest during the first few weeks of titration and attenuates as the gut adapts, but it never fully disappears.

The second mechanism is glycemic. Semaglutide lowers blood glucose on its own. Stacking it on another glucose-lowering drug multiplies that effect, and the result is hypoglycemia.

That is the entire framework. Everything below is a specific application of one of those two ideas.

Insulin: dose reduction is mandatory, not optional

Semaglutide combined with insulin produces a clinically significant hypoglycemia risk. The Ozempic label warns that when semaglutide is added to insulin, the insulin dose should be reduced before starting ^[1]. The same warning appears on Wegovy ^[2]. This is not theoretical. The SUSTAIN and STEP trial programs both required protocolized insulin dose reductions to prevent severe hypoglycemia, and post-marketing reports continue to confirm the signal.

The practical rule prescribers use: when initiating semaglutide in a patient on basal insulin, drop the insulin dose by 20 percent on day one of semaglutide, then retitrate insulin upward based on fasting glucose readings over the following two weeks. If the patient is on basal-bolus insulin, prandial insulin often needs an even larger cut because semaglutide reduces post-meal glucose excursions sharply. Continuous glucose monitor data makes this much safer than fingerstick alone.

Sulfonylureas (glipizide, glyburide, glimepiride): cut the dose

Sulfonylureas push the pancreas to release insulin regardless of blood glucose. Semaglutide also lowers glucose. Stacked together they produce hypoglycemia at rates well above semaglutide alone. The Ozempic label specifically recommends reducing the sulfonylurea dose when starting semaglutide ^[1].

A typical reduction is 50 percent of the sulfonylurea dose at semaglutide initiation, with further adjustment based on glucose monitoring during the four-week dose escalation. Glipizide is the most-studied semaglutide pairing in this class. Many endocrinologists prefer to taper the sulfonylurea off entirely once semaglutide reaches a therapeutic dose, since the cardiovascular and weight benefits favor staying on the GLP-1.

Metformin: safe, commonly combined, no dose change

This is the one combination that does not require adjustment. Metformin and semaglutide are routinely co-prescribed for type 2 diabetes. The trials supporting Ozempic and Rybelsus approval used metformin as a background therapy in most arms. There is no pharmacokinetic interaction of clinical significance, no shared hypoglycemia mechanism (metformin alone rarely causes hypoglycemia), and the combination produces additive A1c reductions and weight loss ^[1][3].

The same logic applies to metformin plus Wegovy for weight loss. Many obesity medicine prescribers continue metformin alongside Wegovy because metformin contributes a modest extra weight-loss effect and the cardiovascular evidence base is strong. SGLT2 inhibitors like Jardiance (empagliflozin) or Forxiga (dapagliflozin) also combine safely with semaglutide. The triple combination of metformin, an SGLT2 inhibitor, and semaglutide is now a common type 2 diabetes regimen.

Oral contraceptives: a real issue early in titration, mostly with Rybelsus

The interaction matters more for oral semaglutide (Rybelsus) than for injectable semaglutide. Rybelsus relies on a permeation enhancer (SNAC) to absorb the peptide across the gastric mucosa, and that absorption is sensitive to anything else in the stomach. The Rybelsus label warns that any oral medication taken too close to a Rybelsus dose may have altered absorption, and it requires at least 30 minutes of fasting after the Rybelsus dose before any other oral medication, food, or beverage ^[3].

For injectable Ozempic and Wegovy, delayed gastric emptying can slow contraceptive pill absorption during the first weeks of titration, particularly if a patient is vomiting from GI side effects. The FDA Wegovy label does not require a backup contraceptive method routinely, but the prescribing information for Mounjaro (a related GLP-1) does. Many obesity medicine clinicians extend the same caution to Wegovy patients on combined oral contraceptives and recommend a backup method (condoms, a copper IUD already in place, or switching to a non-oral hormonal method) during the first four weeks of dose escalation and for four weeks after each dose increase.

Plan B (levonorgestrel emergency contraception) is also taken orally. If a patient on Wegovy who has been vomiting needs Plan B, the absorption question is real. The standard clinical recommendation is to take Plan B as soon as possible, and if vomiting occurs within three hours of the dose, repeat it.

Warfarin and INR-monitored drugs: monitor more often during titration

Warfarin has a narrow therapeutic window and its absorption depends on gastric emptying timing. A 2018 pharmacokinetic study of semaglutide co-administration with warfarin found a small but measurable change in warfarin exposure, primarily a delayed Tmax (the peak absorption shifted later) without a clinically meaningful change in overall AUC ^[5]. The FDA Ozempic label notes the interaction was studied and recommends INR monitoring when starting or stopping semaglutide ^[1].

The practical rule: any patient on warfarin who starts semaglutide should have an INR check at week 2 and week 4 of titration, then at each dose-escalation step. The same caution applies to direct oral anticoagulants (apixaban, rivaroxaban, dabigatran) even though INR monitoring is not used; the absorption window can shift, and any unusual bleeding or thrombotic symptom during semaglutide titration deserves attention.

Thyroid medications: levothyroxine timing matters

Levothyroxine absorption is exquisitely sensitive to gastric pH, food, and any change in upper GI transit. Semaglutide slows gastric emptying, which can blunt or delay levothyroxine absorption. The Rybelsus label specifically warns about this and recommends caution when Rybelsus is co-administered with levothyroxine because Rybelsus increased levothyroxine exposure by about 33 percent in pharmacokinetic studies ^[3].

For Ozempic and Wegovy, the levothyroxine interaction is less dramatic but worth flagging. The standard advice (take levothyroxine on an empty stomach, 30 to 60 minutes before food, with plain water only) is even more important on semaglutide. Many endocrinologists check TSH at four to eight weeks after starting semaglutide in any patient on thyroid replacement, and adjust the levothyroxine dose if needed.

Opioids: additive gut slowing, plus a real risk of severe constipation

Opioids slow gastric emptying and intestinal transit through mu-receptor agonism in the gut wall. Semaglutide slows gastric emptying through a different mechanism, but the downstream effect is the same. Patients on chronic opioid therapy (oxycodone, hydrocodone, morphine, tramadol) who add semaglutide have a higher rate of severe constipation, nausea, and in rare cases gastroparesis-like presentations. The FDA Ozempic label notes that semaglutide should be used with caution in patients with severe gastrointestinal disease, and chronic opioid use is an obvious risk factor for that category ^[1].

This is not a contraindication. Patients with chronic pain who legitimately need both medications can usually combine them with prophylactic bowel-regimen support: scheduled polyethylene glycol (Miralax), increased water intake, and dose-titration of semaglutide slower than the standard four-week protocol if GI tolerance is borderline.

Other GLP-1 receptor agonists: do not combine

Semaglutide and another GLP-1 (liraglutide, dulaglutide, tirzepatide) should never be used together. The drugs work on the same receptor, the dose-response is not additive in a useful way, and the side-effect profile compounds aggressively. All three of the major prescribing-information documents in this class state that GLP-1 agonists should not be coadministered with other GLP-1 agonists.

The switching pathway is the safe alternative. Patients moving from Saxenda (liraglutide) to Wegovy stop liraglutide on day one of Wegovy and start at the 0.25 mg Wegovy initiation dose without a washout period; liraglutide's short half-life (around 13 hours) means it clears quickly. Patients moving from Ozempic to Wegovy can usually start Wegovy at a dose roughly matching their current Ozempic dose because both products are semaglutide and the only difference is the indication and titration schedule. Patients switching from semaglutide to tirzepatide stop semaglutide and start tirzepatide at 2.5 mg without overlap.

Antidepressants, the serotonin syndrome question, and bupropion

This is a topic where internet anxiety has outrun the actual evidence. Semaglutide has no direct serotonergic activity. There is no pharmacodynamic mechanism by which it can contribute to serotonin syndrome. The concern circulating online about combining semaglutide with SSRIs (sertraline, escitalopram, fluoxetine) or SNRIs (venlafaxine, duloxetine) or MAOIs is not supported by the FDA label or by published case data.

What is real: semaglutide's GI side effects (nausea, vomiting, early satiety) can be additive with SSRI-induced GI side effects during the first weeks of an SSRI start. If a patient starts an SSRI and semaglutide in the same week, the GI tolerance will be miserable. Stagger the starts by at least four weeks when possible.

Bupropion (Wellbutrin) is sometimes combined with semaglutide for weight loss. The combination is generally safe. The branded combination drug Contrave is bupropion plus naltrexone, and combining Contrave with semaglutide is theoretically possible but not well-studied; most obesity medicine clinicians will pick one or the other rather than stack them.

Trazodone, buspirone, and gabapentin have no significant pharmacokinetic interaction with semaglutide.

Stimulants and other weight-loss drugs: usually not combined

Phentermine is a sympathomimetic appetite suppressant. Semaglutide is a GLP-1 agonist. The two work through different mechanisms, and some obesity medicine clinicians combine them off-label, particularly for patients whose weight loss has plateaued on semaglutide alone. There is no direct pharmacokinetic interaction. There is a theoretical cardiovascular concern (phentermine raises heart rate, semaglutide modestly raises heart rate), and the combination should not be used in patients with uncontrolled hypertension, known cardiovascular disease, or arrhythmia. Qsymia (phentermine plus topiramate) carries the same logic.

Adderall (amphetamine salts) and other ADHD stimulants share the cardiovascular caution but have no metabolic interaction with semaglutide. Patients with well-controlled ADHD on a stable Adderall dose generally continue it on semaglutide without modification, with attention to hydration since both drugs reduce appetite and thirst cues.

Orlistat blocks fat absorption. Combining it with semaglutide is pharmacologically reasonable but produces brutal GI side effects (the diarrhea and fat malabsorption from orlistat stack on semaglutide nausea), and the marginal weight-loss benefit usually does not justify the combination.

HCG injections for weight loss have no scientific evidence base and should not be combined with semaglutide.

NSAIDs, acetaminophen, and over-the-counter pain relievers

This is the category where most patient questions land. There is no FDA-labeled drug interaction between semaglutide and ibuprofen (Advil), naproxen (Aleve), meloxicam, or acetaminophen (Tylenol). Patients can take these for routine pain on semaglutide without modification.

The clinical caution is downstream of dehydration. Semaglutide causes nausea and vomiting in a substantial fraction of patients during titration. Dehydration raises kidney injury risk. NSAIDs (ibuprofen, naproxen, meloxicam) reduce renal perfusion. A patient who has been vomiting for 48 hours, is dehydrated, and takes high-dose ibuprofen for a headache is at meaningful risk of acute kidney injury. The advice is not to avoid NSAIDs while on semaglutide, but to avoid them during active GI side effects, and to favor acetaminophen for pain control during titration weeks.

Pepto-Bismol (bismuth subsalicylate) is generally fine for transient GI symptoms on semaglutide, with the usual salicylate cautions (avoid in patients on anticoagulants, avoid in children with viral illness). NyQuil combines acetaminophen with dextromethorphan and doxylamine; no semaglutide-specific interaction, but the sedating antihistamine plus dehydration risk during a GI side-effect episode is worth flagging.

Acid suppressants: omeprazole, PPIs, H2 blockers

Proton pump inhibitors (omeprazole, pantoprazole, esomeprazole) raise gastric pH. For injectable semaglutide, this does not matter. For Rybelsus, gastric pH affects the SNAC permeation enhancer's function, and the label warns that concomitant PPI use may reduce Rybelsus absorption ^[3]. Patients on chronic PPI therapy who need oral semaglutide may need injectable semaglutide instead.

H2 blockers (famotidine, ranitidine where still available) have less effect on gastric pH and are less of a concern, though the same general principle applies for Rybelsus.

Cardiovascular medications: lisinopril, amlodipine, statins

Antihypertensives have no clinically significant interaction with semaglutide. Lisinopril, losartan, amlodipine, and hydrochlorothiazide are all routinely co-prescribed without issue. Semaglutide does produce modest blood pressure reduction on its own (a few mmHg systolic), so patients on tight blood pressure control should monitor for hypotension during titration and report any lightheadedness.

Statins (atorvastatin, simvastatin, rosuvastatin) have no pharmacokinetic interaction with semaglutide. The combination is in fact the standard of care for patients with type 2 diabetes and elevated cardiovascular risk. The SELECT trial showed semaglutide reduced major adverse cardiovascular events in patients with established cardiovascular disease, most of whom were on a statin.

Antibiotics and antifungals

Amoxicillin, azithromycin, ciprofloxacin, doxycycline, and most other oral antibiotics have no metabolic interaction with semaglutide. Delayed gastric emptying can shift the absorption window slightly, but for a course of antibiotics this is rarely clinically meaningful. The main practical issue is that antibiotics commonly cause nausea and diarrhea on their own, which compounds semaglutide GI side effects. A patient on a 10-day course of amoxicillin-clavulanate during semaglutide titration will have a rough week.

Oral fluconazole and other azole antifungals are also fine with semaglutide. There is no shared metabolic pathway.

Supplements: berberine, melatonin, ashwagandha, creatine, collagen

Most supplements have minimal interaction evidence with semaglutide because they are not studied. The pragmatic guidance:

• Berberine: lowers blood glucose. Theoretically additive hypoglycemia risk, though much milder than insulin or sulfonylureas. Reasonable to use, monitor glucose if on a diabetic regimen.
• Melatonin: no interaction. Safe at standard sleep doses.
• Ashwagandha: no documented interaction. Safe at standard doses.
• Creatine: no interaction. Common in patients trying to preserve lean mass during weight loss on semaglutide.
• Collagen peptides: no interaction. Common protein supplement.
• Bioma and other probiotic blends: no interaction. May help with constipation during semaglutide titration.

The supplement category most likely to cause trouble is anything that lowers blood glucose (chromium picolinate at high doses, gymnema, bitter melon) stacked on a diabetic regimen with insulin or sulfonylureas.

Alcohol and grapefruit

Alcohol has no pharmacokinetic interaction with semaglutide, but it lowers blood glucose, contributes to dehydration, and worsens nausea during titration. Moderation is the standard advice. Patients who are on insulin or sulfonylureas plus semaglutide and who drink should be especially careful about nocturnal hypoglycemia.

Grapefruit juice is famous for CYP3A4 inhibition. Semaglutide is not metabolized through CYP3A4. There is no grapefruit interaction with semaglutide.

Bariatric surgery considerations

Patients with a history of bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy, duodenal switch) can use semaglutide, but the pharmacokinetics differ. After Roux-en-Y, gastric emptying is already altered and the gastric remnant is small. Semaglutide's effect on gastric emptying is less relevant, but absorption of oral comedications is significantly altered by the anatomical change rather than by semaglutide itself. Rybelsus is generally not used after bariatric surgery because the SNAC absorption mechanism depends on a normal stomach.

Patients planning bariatric surgery while on semaglutide should discuss timing with their surgical team. Most surgical programs require holding GLP-1 agonists for one to two weeks pre-operatively because of concerns about retained gastric contents and aspiration risk during anesthesia induction. The American Society of Anesthesiologists has published guidance on this. After surgery, semaglutide can usually be resumed once oral intake is established, often at a lower starting dose.

Common questions about semaglutide drug interactions

Can I take metformin and Ozempic together?

Yes. Metformin plus semaglutide is one of the most commonly prescribed type 2 diabetes regimens. No dose adjustment is needed, and the combination produces additive A1c and weight reductions.

Can I take ibuprofen on semaglutide?

Yes for routine use, but avoid high-dose or chronic NSAIDs during active GI side effects. Dehydration from semaglutide-induced vomiting plus NSAIDs raises kidney injury risk. Acetaminophen is safer during titration weeks.

Does Ozempic affect birth control?

For injectable Ozempic the effect on oral contraceptives is small and not labeled as a routine concern. For Rybelsus, take the dose 30 minutes before any other oral medication including the pill. A backup method during titration is a reasonable precaution.

Can you take Wegovy and Wellbutrin together?

Yes. There is no pharmacokinetic interaction between semaglutide and bupropion. The combination is sometimes used for weight loss with bupropion's appetite-suppressant effect.

Can you take semaglutide with insulin?

Yes, but the insulin dose must be reduced before starting semaglutide. Typically a 20 percent reduction in basal insulin at semaglutide initiation, with further adjustment based on glucose monitoring.

Can you take phentermine and semaglutide together?

Off-label combinations exist and some obesity medicine prescribers use them. There is no direct pharmacokinetic interaction. Avoid in patients with uncontrolled hypertension or cardiovascular disease because both drugs modestly raise heart rate.

Can you take antibiotics while on semaglutide?

Yes. Common oral antibiotics like amoxicillin, azithromycin, and doxycycline have no meaningful interaction with semaglutide. Expect worse GI tolerance during the antibiotic course since both can cause nausea.

Can I take Tylenol with semaglutide?

Yes. Acetaminophen has no interaction with semaglutide and is the preferred OTC analgesic during titration weeks when NSAIDs may be riskier.

Can I switch from Ozempic to Wegovy?

Yes. Both are semaglutide. The switch is usually done by matching the current Ozempic dose to the closest Wegovy dose and continuing on a weekly schedule. No washout is needed.

Can you take Jardiance and Wegovy together?

Yes. SGLT2 inhibitors like Jardiance combine safely with semaglutide. The combination is common in type 2 diabetes regimens.

Does grapefruit interfere with Ozempic?

No. Semaglutide is not metabolized by CYP3A4. The grapefruit interaction that affects many other drugs does not apply.

Can you combine semaglutide and tirzepatide?

No. Both act on the GLP-1 receptor and should not be used together. Switch from one to the other; do not stack them.

Does semaglutide interact with thyroid medication?

Levothyroxine absorption can be affected, especially with Rybelsus. Check TSH four to eight weeks after starting semaglutide and adjust the levothyroxine dose if needed.

Can I take semaglutide with high blood pressure medication?

Yes. Lisinopril, amlodipine, losartan, and hydrochlorothiazide all combine safely. Watch for mild hypotension since semaglutide itself lowers blood pressure slightly.

Can you take statins with Wegovy?

Yes. Atorvastatin, simvastatin, and rosuvastatin have no interaction with semaglutide. The combination is standard of care for patients with diabetes and elevated cardiovascular risk.

What this article does not cover

This page is the general drug-interaction map for semaglutide. Specific combinations (semaglutide plus a single named drug) that need their own detailed dosing protocols, like the semaglutide-insulin titration schedule or the semaglutide-bariatric perioperative protocol, have their own dedicated pages on this site. The framework above applies to almost every interaction question that comes up in clinical practice: identify whether the other drug is glucose-lowering (hypoglycemia risk) or absorbed orally with a narrow therapeutic window (gastric emptying risk), and adjust from there.